マイクロバイオーム診断の世界市場、2024-2031年

世界のマイクロバイオーム診断市場は予測期間（2024-2031年）にCAGR 11.4％で成長すると予測されます。ヒトマイクロバイオームに対する需要の高まりとともに、16S rRNAシーケンス、ショットガン・メタゲノミクス、メタトランスクリプトミクスなどの先端技術の採用が拡大していることが、世界の市場の成長を支える主要因となっています。市場参入企業はマイクロバイオーム診断ソリューションを導入し、市場の成長をさらに後押ししています。これらの共同研究を通じて、業界企業と学術研究者はマイクロバイオームに基づく新しい診断製品を開発し、健康と疾患におけるマイクロバイオームの役割の理解を進めるために協力しています。

機械学習とバイオインフォマティクスの統合の進展

バイオインフォマティクスや機械学習などの計算技術の発展により、マイクロバイオーム特異的診断の検出が容易になり、特定の疾患に対する正確な診断が可能になった。健康状態に関連するパターンや潜在的なバイオマーカーを特定するために、多くのマイクロバイオームデータで計算ツールが活用されるようになってきています。機械学習技術のさらなる急速な発展により、マイクロバイオーム研究のデータ密度の高い分野は、幅広い疾患を対象とした新規の治療、診断、予後のアプリケーションのために開拓され、プレシジョンメディシンの時代におけるヘルスケアの実践を大幅に改善する可能性があります。

マイクロバイオーム機能活動のためのマルチオミクスデータの採用増加

マルチオミクスアプローチからのデータを統合することで、マイクロバイオームの機能に関する新たな知見が得られます。例えば、メタゲノミクスとメタトランスクリプトミクスを統合することで、遺伝子の転写活性化や抑制を示す転写産物/遺伝子比の計算が可能になります。さらに、マイクロバイオームのマルチオミクス研究によって、宿主と微生物の相互作用の根底にあるメカニズムについての知見を得ることができます。より多くのオミックス層が検討されるにつれて、それらを統合するための高度な統計手法がますます必要とされています。

市場セグメンテーション

試薬・キットが最大セグメントとして浮上

マイクロバイオーム診断の世界市場は、製品別に試薬・キットと機器に細分化されます。このうち、試薬・キットのサブセグメントが市場の最大シェアを占めると予想されます。同分野の成長を支える主な要因としては、マイクロバイオーム診断や疾患モニタリング、予後予測、治療効果予測などのための試薬・キットの採用が拡大していることが挙げられます。例えば、MACHEREY-NAGEL GmbH &Co.KG社は、マイクロバイオームおよびメタゲノム解析のために、便、土壌、バイオフィルムを含む様々なサンプルインプットからDNAを精製するように設計された試薬およびキットを提供しています。

市場セグメンテーション：学術・研究機関が大きな市場シェアを占める

エンドユーザーの中では、マイクロバイオーム診断研究のための微生物研究機関の増加により、学術・研究機関サブセグメントがかなりの市場シェアを占めています。例えば、2023年3月にシーダーズ・サイナイがマイクロバイオーム研究機関を立ち上げ、マイクロバイオームの研究者を支援しています。技術的、実用的、概念的な進歩を含むマイクロバイオーム研究の主要な進歩は、疾患診断、医薬品開発、個別化介入の強化につながります。

地域別展望

世界のマイクロバイオーム診断市場は、北米（米国、カナダ）、欧州（英国、イタリア、スペイン、ドイツ、フランス、その他欧州地域）、アジア太平洋地域（インド、中国、日本、韓国、その他アジア地域）、世界のその他の地域（中東とアフリカ、ラテンアメリカ）を含む地域によってさらに細分化されます。

欧州におけるバイオテクノロジーおよび製薬企業の増加

• 同地域における疾患の発生率の増加、マイクロバイオーム研究のための学術機関との連携、個別化医療に対する需要の高まり。
• 同地域の市場参入企業は、マイクロバイオームのフィクション活動のために、マルチオミクスデータを利用した先進技術ベースのマイクロバイオーム診断を提供しています。

北米が主要市場シェアを占める

全地域の中で北米が大きなシェアを占めているのは、マイクロバイオーム診断を提供するプロバイダーの数が非常に多いためです。高度な医療分野の利用可能性や重要な新興製品メーカーなどの要因が市場成長を促進しています。また、病原体特異的な試薬・診断キットの開発・商品化により、サンプルの使用法が改善され、特定の疾患診断に明確な臨床技術が採用されるようになった。この地域の市場プレイヤーは、先進的なマイクロバイオーム診断法を開発しています。例えば、2023年1月、Micronoma Inc.はマイクロバイオーム駆動型リキッドバイオプシー・プラットフォームによる早期がん検出を開発しました。OncobiotaLUNGアッセイは、肺がんを初期段階で検出するために開発された血液マイクロバイオーム駆動型リキッドバイオプシーです。

目次

第1章 レポート概要

• 業界の現状分析と成長ポテンシャルの展望
• 調査方法とツール
• 市場内訳
  • セグメント別
  • 地域別

第2章 市場概要と洞察

• 調査範囲
• アナリストの洞察と現在の市場動向
  • 主な調査結果
  • 推奨事項
  • 結論

第3章 競合情勢

• 主要企業分析
• Illumina, Inc.
  • 概要
  • 財務分析
  • SWOT分析
  • 最近の動向
• Merck KGaA
  • 会社概要
  • 財務分析
  • SWOT分析
  • 最近の動向
• Thermo Fisher Scientific Inc.
  • 概要
  • 財務分析
  • SWOT分析
  • 最近の動向
• 主要戦略分析

第4章 市場セグメンテーション

• マイクロバイオーム診断の世界市場：製品別
  • 試薬・キット
  • 機器
• マイクロバイオーム診断の世界市場：技術別
  • S rRNAシーケンシング
  • ショットガンメタゲノミクス
  • メタトランスクリプトミクス
  • その他（バイオマーカー）
• マイクロバイオーム診断の世界市場：エンドユーザー別
  • 病院
  • 学術・研究機関
  • バイオテクノロジー・製薬企業

第5章 地域分析

• 北米
  • 米国
  • カナダ
• 欧州
  • 英国
  • ドイツ
  • イタリア
  • スペイン
  • フランス
  • その他欧州
• アジア太平洋
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• 世界のその他の地域

第6章 企業プロファイル

• Biome Diagnostics GmbH
• Bio-Rad Laboratories, Inc.
• Biota Technology
• CD Genomics
• CeGaT GmbH
• CosmosID
• DNA Genotek Inc.
• Genova Diagnostics Inc.
• Microbiome Insights
• Microbiome Research Pvt. Ltd.
• One Codex, Inc.
• OraSure Technologies, Inc
• QIAGEN GmbH
• Resphera Biosciences, LLC
• Takara Bio Inc.
• ViennaLab Diagnostics GmbH
• Viome Life Sciences, Inc.
• Zymo Research Corp.

LIST OF TABLES

• 1.GLOBAL MICROBIOME DIAGNOSTIC MARKET RESEARCH AND ANALYSIS BY PRODUCT, 2023-2031 ($ MILLION)
• 2.GLOBAL MICROBIOME DIAGNOSTIC REAGENTS & KITS MARKET RESEARCH AND ANALYSIS BY REGION, 2023-2031 ($ MILLION)
• 3.GLOBAL MICROBIOME DIAGNOSTIC INSTRUMENTS MARKET RESEARCH AND ANALYSIS BY REGION, 2023-2031 ($ MILLION)
• 4.GLOBAL MICROBIOME DIAGNOSTIC MARKET RESEARCH AND ANALYSIS BY TECHNOLOGY, 2023-2031 ($ MILLION)
• 5.GLOBAL 16S RRNA SEQUENCING-BASED MICROBIOME DIAGNOSTIC MARKET RESEARCH AND ANALYSIS BY REGION, 2023-2031 ($ MILLION)
• 6.GLOBAL SHOT GUN METAGENOMICS- BASED MICROBIOME DIAGNOSTIC MARKET RESEARCH AND ANALYSIS BY REGION, 2023-2031 ($ MILLION)
• 7.GLOBAL METATRANSCRIPTOMICS BASED MICROBIOME DIAGNOSTIC MARKET RESEARCH AND ANALYSIS BY REGION, 2023-2031 ($ MILLION)
• 8.GLOBAL OTHER TECHNOLOGY-BASED MICROBIOME DIAGNOSTIC MARKET RESEARCH AND ANALYSIS BY REGION, 2023-2031 ($ MILLION)
• 9.GLOBAL MICROBIOME DIAGNOSTIC MARKET RESEARCH AND ANALYSIS BY END-USERS, 2023-2031 ($ MILLION)
• 10.GLOBAL MICROBIOME DIAGNOSTIC FOR HOSPITALS MARKET RESEARCH AND ANALYSIS BY REGION, 2023-2031 ($ MILLION)
• 11.GLOBAL MICROBIOME DIAGNOSTIC FOR ACADEMIC AND RESEARCH INSTITUTES MARKET RESEARCH AND ANALYSIS BY REGION, 2023-2031 ($ MILLION)
• 12.GLOBAL MICROBIOME DIAGNOSTIC FOR BIOTECHNOLOGY AND PHARMACEUTICAL COMPANIES MARKET RESEARCH AND ANALYSIS BY REGION, 2023-2031 ($ MILLION)
• 13.GLOBAL MICROBIOME DIAGNOSTIC MARKET RESEARCH AND ANALYSIS BY REGION, 2023-2031 ($ MILLION)
• 14.NORTH AMERICAN MICROBIOME DIAGNOSTIC MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2023-2031 ($ MILLION)
• 15.NORTH AMERICAN MICROBIOME DIAGNOSTIC MARKET RESEARCH AND ANALYSIS BY PRODUCT, 2023-2031 ($ MILLION)
• 16.NORTH AMERICAN MICROBIOME DIAGNOSTIC MARKET RESEARCH AND ANALYSIS BY TECHNOLOGY, 2023-2031 ($ MILLION)
• 17.NORTH AMERICAN MICROBIOME DIAGNOSTIC MARKET RESEARCH AND ANALYSIS BY END-USERS, 2023-2031 ($ MILLION)
• 18.EUROPEAN MICROBIOME DIAGNOSTIC MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2023-2031 ($ MILLION)
• 19.EUROPEAN MICROBIOME DIAGNOSTIC MARKET RESEARCH AND ANALYSIS BY PRODUCT, 2023-2031 ($ MILLION)
• 20.EUROPEAN MICROBIOME DIAGNOSTIC MARKET RESEARCH AND ANALYSIS BY TECHNOLOGY, 2023-2031 ($ MILLION)
• 21.EUROPEAN MICROBIOME DIAGNOSTIC MARKET RESEARCH AND ANALYSIS BY END-USERS, 2023-2031 ($ MILLION)
• 22.ASIA-PACIFIC MICROBIOME DIAGNOSTIC MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2023-2031 ($ MILLION)
• 23.ASIA-PACIFIC MICROBIOME DIAGNOSTIC MARKET RESEARCH AND ANALYSIS BY PRODUCT, 2023-2031 ($ MILLION)
• 24.ASIA-PACIFIC MICROBIOME DIAGNOSTIC MARKET RESEARCH AND ANALYSIS BY TECHNOLOGY, 2023-2031 ($ MILLION)
• 25.ASIA-PACIFIC MICROBIOME DIAGNOSTIC MARKET RESEARCH AND ANALYSIS BY END-USERS, 2023-2031 ($ MILLION)
• 26.REST OF THE WORLD MICROBIOME DIAGNOSTIC MARKET RESEARCH AND ANALYSIS BY REGION, 2023-2031 ($ MILLION)
• 27.REST OF THE WORLD MICROBIOME DIAGNOSTIC MARKET RESEARCH AND ANALYSIS BY PRODUCT, 2023-2031 ($ MILLION)
• 28.REST OF THE WORLD MICROBIOME DIAGNOSTIC MARKET RESEARCH AND ANALYSIS BY TECHNOLOGY, 2023-2031 ($ MILLION)
• 29.REST OF THE WORLD MICROBIOME DIAGNOSTIC MARKET RESEARCH AND ANALYSIS BY END-USERS, 2023-2031 ($ MILLION)

LIST OF FIGURES

• 1.GLOBAL MICROBIOME DIAGNOSTIC MARKET SHARE BY PRODUCT, 2023 VS 2031 (%)
• 2.GLOBAL MICROBIOME DIAGNOSTIC REAGENTS & KITS MARKET SHARE BY REGION, 2023 VS 2031 (%)
• 3.GLOBAL MICROBIOME DIAGNOSTIC INSTRUMENTS MARKET SHARE BY REGION, 2023 VS 2031 (%)
• 4.GLOBAL MICROBIOME DIAGNOSTIC MARKET SHARE BY TECHNOLOGY, 2023 VS 2031 (%)
• 5.GLOBAL 16S RRNA SEQUENCING-BASED MICROBIOME DIAGNOSTIC MARKET SHARE BY REGION, 2023 VS 2031 (%)
• 6.GLOBAL SHOT GUN METAGENOMICS-BASED MICROBIOME DIAGNOSTIC MARKET SHARE BY REGION, 2023 VS 2031 (%)
• 7.GLOBAL METATRANSCRIPTOMICS-BASED MICROBIOME DIAGNOSTIC MARKET SHARE BY REGION, 2023 VS 2031 (%)
• 8.GLOBAL OTHER TECHNOLOGY-BASED MICROBIOME DIAGNOSTIC MARKET SHARE BY REGION, 2023 VS 2031 (%)
• 9.GLOBAL MICROBIOME DIAGNOSTIC MARKET SHARE BY END-USERS, 2023 VS 2031 (%)
• 10.GLOBAL MICROBIOME DIAGNOSTIC FOR HOSPITALS MARKET SHARE BY REGION, 2023 VS 2031 (%)
• 11.GLOBAL MICROBIOME DIAGNOSTIC FOR ACADEMIC AND RESEARCH INSTITUTES MARKET SHARE BY REGION, 2023 VS 2031 (%)
• 12.GLOBAL MICROBIOME DIAGNOSTIC FOR BIOTECHNOLOGY AND PHARMACEUTICAL COMPANIES MARKET SHARE BY REGION, 2023 VS 2031 (%)
• 13.GLOBAL MICROBIOME DIAGNOSTIC MARKET SHARE BY REGION, 2023 VS 2031 (%)
• 14.US MICROBIOME DIAGNOSTIC MARKET SIZE, 2023-2031 ($ MILLION)
• 15.CANADA MICROBIOME DIAGNOSTIC MARKET SIZE, 2023-2031 ($ MILLION)
• 16.UK MICROBIOME DIAGNOSTIC MARKET SIZE, 2023-2031 ($ MILLION)
• 17.FRANCE MICROBIOME DIAGNOSTIC MARKET SIZE, 2023-2031 ($ MILLION)
• 18.GERMANY MICROBIOME DIAGNOSTIC MARKET SIZE, 2023-2031 ($ MILLION)
• 19.ITALY MICROBIOME DIAGNOSTIC MARKET SIZE, 2023-2031 ($ MILLION)
• 20.SPAIN MICROBIOME DIAGNOSTIC MARKET SIZE, 2023-2031 ($ MILLION)
• 21.REST OF EUROPE MICROBIOME DIAGNOSTIC MARKET SIZE, 2023-2031 ($ MILLION)
• 22.INDIA MICROBIOME DIAGNOSTIC MARKET SIZE, 2023-2031 ($ MILLION)
• 23.CHINA MICROBIOME DIAGNOSTIC MARKET SIZE, 2023-2031 ($ MILLION)
• 24.JAPAN MICROBIOME DIAGNOSTIC MARKET SIZE, 2023-2031 ($ MILLION)
• 25.SOUTH KOREA MICROBIOME DIAGNOSTIC MARKET SIZE, 2023-2031 ($ MILLION)
• 26.REST OF ASIA-PACIFIC MICROBIOME DIAGNOSTIC MARKET SIZE, 2023-2031 ($ MILLION)
• 27.LATIN AMERICA MICROBIOME DIAGNOSTIC MARKET SIZE, 2023-2031 ($ MILLION)
• 28.THE MIDDLE EAST AND AFRICA MICROBIOME DIAGNOSTIC MARKET SIZE, 2023-2031 ($ MILLION)

Global Microbiome Diagnostic Market Size, Share & Trends Analysis Report by Product (Reagents & Kits, and Instruments), by Technology (16S rRNA Sequencing, Shot Gun Metagenomics, Metatranscriptomics, and Other), and by End-Users (Hospitals, Academic and Research Institutes and Biotechnology, and Pharmaceutical Companies) Forecast Period (2024-2031)

Global microbiome diagnostic market is anticipated to grow at a CAGR of 11.4% during the forecast period (2024-2031). The growing adoption of advanced technologies such as 16S rRNA sequencing, shotgun metagenomics, and metatranscriptomics with increasing demand for the human microbiome are key factors supporting the growth of the market globally. The market players are introducing microbiome diagnostic solutions that further bolster the market growth. Through these collaborations, industry companies and academic researchers work together to develop new diagnostic products based on the microbiome and to advance understanding of the microbiome's role in health and disease.

Market Dynamics

Increasing Integration of machine learning and bioinformatics

Growing developments in computational technology, such as bioinformatics and machine learning, have made it easy to detect microbiome-specific diagnoses, resulting in accurate diagnoses for certain diseases. Computational tools are increasingly utilized in a large number of microbiome data for the identification of patterns and potential biomarkers associated with health conditions. Further rapid development of machine learning techniques has opened up the data-dense field of microbiome research for novel therapeutic, diagnostic, and prognostic applications targeting a wide range of disorders, which could substantially improve healthcare practices in the era of precision medicine.

Increasing adoption of multi-omics data for microbiome functional activities

Increasing adoption of multi-omics data for microbiome fictional activities with integrating the data from multi-omic approaches provides additional insight into microbiome functions. For instance, integrating metagenomics and metatranscriptomics provides a calculation of transcript/gene ratios, which is indicative of gene transcriptional activation or repression. Additionally, multi-omic studies of the microbiome can provide insight into the mechanisms underlying host-microbe interactions. As more omics layers are considered, increasingly sophisticated statistical methods are required to integrate them.

Market Segmentation

Our in-depth analysis of the global microbiome diagnostic market includes the following segments by product, technology and end-users:

• Based on product, the market is sub-segmented into reagents & kits and instruments.
• Based on technology, the market is sub-segmented into 16S rRNA sequencing, shotgun metagenomics, metatranscriptomics, and other (biomarkers).
• Based on end-users, the market is sub-segmented into hospitals, academic and research institutes, and biotechnology and pharmaceutical companies.

Reagents & Kits is Projected to Emerge as the Largest Segment

Based on the product, the global microbiome diagnostic market is sub-segmented into reagents & kits and instruments. Among these, the reagents & kits sub-segment is expected to hold the largest share of the market. The primary factor supporting the segment's growth includes the growing adoption of reagents and kits for microbiome diagnosing and monitoring disease, for providing prognoses, and for predicting treatment responses. For instance, MACHEREY-NAGEL GmbH & Co. KG offers reagents & kits designed to purify DNA from a variety of sample inputs, including stool, soil, and biofilms for microbiome and metagenome analysis.

Academic and Research Institutes Sub-segment to Hold a Considerable Market Share

Among the end-users, the academic and research institutes sub-segment holds a considerable market share owing to the increasing number of microbial research institutes for microbiome diagnostic studies. For instance, in March 2023, Cedars-Sinai launched a microbiome research institute that supports investigators studying of microbiome includes a diverse collection of bacteria, fungi, and viruses that live in and on the human body, and play a role in health. The major advancements in microbiome research, including technical, practical, and conceptual advancements, result in enhanced disease diagnosis, medicine development, and personalized interventions.

Regional Outlook

The global microbiome diagnostic market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia), and the Rest of the World (the Middle East & Africa, and Latin America).

An increasing number of biotechnology and pharmaceutical companies in Europe

• Increasing incidences of diseases, the collaboration between microbiome research and academic institutes for microbiome research, and growing demand for personalized medicine in the region.
• Market players in the region provide advanced technology-based microbiome diagnosis using multi-omics data for microbiome fictional activities.

North America Holds Major Market Share

Among all the regions, North America holds a significant share owing to the presence of an enormous number of providers offering microbiome diagnostics. Factors such as the availability of the advanced health sector and the critical emerging product manufacturers are driving the market growth. In addition, the development and commercialization of pathogen-specific reagent/diagnostic kits have resulted in improved sample usage and the adoption of a well-defined clinical technique for specific disease diagnoses. The market players in the region are developing advanced microbiome diagnostics. For instance, in January 2023, Micronoma Inc. developed early cancer detection with a microbiome-driven liquid biopsy platform. The OncobiotaLUNG assay is the blood microbiome-driven liquid biopsy created to detect lung carcinomas in their earliest stages.

Market Players Outlook

The major companies serving the global microbiome diagnostic market include Bio-Rad Laboratories, Inc., Illumina, Inc., Merck KGaA, Takara Bio Inc., and Thermo Fisher Scientific Inc., among others. The market players are increasingly focusing on business expansion and product development by applying strategies such as collaborations, mergers, and acquisitions to stay competitive in the market. For instance,

• In June 2023, Biome Diagnostics GmbH and SanusX partnered for diagnostics and applications related to the intestinal microbiome for growth in innovative diagnostic procedures with SanusX.BiomeDx utilizes machine learning and artificial intelligence to interpret the intestinal microbiome for medical purposes.
• In February 2023, Microba launched next-generation healthcare testing MetaXplore(TM). The MetaXplore(TM) range provides diagnostic gastrointestinal health testing together with metagenomic gut microbiome analysis. The MetaXplore(TM) test range is expected to expand the total addressable market for Microba's testing products.
• In June 2021, Illumina and Microba Life Sciences partnered to accelerate microbiome research. The partnership brings together Illumina's NGS tools and Microba's high-quality proprietary gut microbiome analysis platform to generate the accurate metagenomic data that researchers require to fuel discoveries.

The Report Covers:

• Market value data analysis of 2023 and forecast to 2031.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the global microbiome diagnostic market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies.
• Competitive strategies by identifying 'who-stands-where' in the market.

Table of Contents

1.Report Summary

• Current Industry Analysis and Growth Potential Outlook
• 1.1.Research Methods and Tools
• 1.2.Market Breakdown
  • 1.2.1.By Segments
  • 1.2.2.By Region

2.Market Overview and Insights

• 2.1.Scope of the Report
• 2.2.Analyst Insight & Current Market Trends
  • 2.2.1.Key Findings
  • 2.2.2.Recommendations
  • 2.2.3.Conclusion

3.Competitive Landscape

• 3.1.Key Company Analysis
• 3.2.Illumina, Inc.
  • 3.2.1.Overview
  • 3.2.2.Financial Analysis
  • 3.2.3.SWOT Analysis
  • 3.2.4.Recent Developments
• 3.3.Merck KGaA
  • 3.3.1.Overview
  • 3.3.2.Financial Analysis
  • 3.3.3.SWOT Analysis
  • 3.3.4.Recent Developments
• 3.4.Thermo Fisher Scientific Inc.
  • 3.4.1.Overview
  • 3.4.2.Financial Analysis
  • 3.4.3.SWOT Analysis
  • 3.4.4.Recent Developments
• 3.5.Key Strategy Analysis

4.Market Segmentation

• 4.1.Global Microbiome Diagnostic Market by Product
  • 4.1.1.Reagents & Kits
  • 4.1.2.Instruments
• 4.2.Global Microbiome Diagnostic Market by Technology
  • 4.2.1.16S rRNA Sequencing
  • 4.2.2.Shot Gun Metagenomics
  • 4.2.3.Metatranscriptomics
  • 4.2.4.Other (Biomarkers)
• 4.3.Global Microbiome Diagnostic Market by End-Users
  • 4.3.1.Hospitals
  • 4.3.2.Academic and Research Institutes
  • 4.3.3.Biotechnology and Pharmaceutical Companies

5.Regional Analysis

• 5.1.North America
  • 5.1.1.United States
  • 5.1.2.Canada
• 5.2.Europe
  • 5.2.1.UK
  • 5.2.2.Germany
  • 5.2.3.Italy
  • 5.2.4.Spain
  • 5.2.5.France
  • 5.2.6.Rest of Europe
• 5.3.Asia-Pacific
  • 5.3.1.China
  • 5.3.2.India
  • 5.3.3.Japan
  • 5.3.4.South Korea
  • 5.3.5.Rest of Asia-Pacific
• 5.4.Rest of the World

6.Company Profiles

• 6.1.Biome Diagnostics GmbH
• 6.2.Bio-Rad Laboratories, Inc.
• 6.3.Biota Technology
• 6.4.CD Genomics
• 6.5.CeGaT GmbH
• 6.6.CosmosID
• 6.7.DNA Genotek Inc.
• 6.8.Genova Diagnostics Inc.
• 6.9.Microbiome Insights
• 6.10.Microbiome Research Pvt. Ltd.
• 6.11.One Codex, Inc.
• 6.12.OraSure Technologies, Inc
• 6.13.QIAGEN GmbH
• 6.14.Resphera Biosciences, LLC
• 6.15.Takara Bio Inc.
• 6.16.ViennaLab Diagnostics GmbH
• 6.17.Viome Life Sciences, Inc.
• 6.18.Zymo Research Corp.